Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
BUSINESS
Lenvima-Keytruda Combo’s Liver Cancer Trial Halted after OS Miss
Eisai and its US ally Merck have discontinued a PIII trial testing the combination therapy of Lenvima (lenvatinib) and Keytruda (pembrolizumab) with transarterial chemoembolization (TACE) in patients with unresectable, non-metastatic hepatocellular carcinoma (HCC). The partners said on October 29 that…
To read the full story
Related Article
- Lenvima/Keytruda Combo Misses OS Goal in 1st Line GI Cancer Trial
January 27, 2025
- Lenvima/Keytruda Added to TACE Extend PFS in HCC
September 18, 2024
- Lenvima-Keytruda for HCC Misses PIII Primary Goal: Eisai/Merck
September 13, 2022
BUSINESS
- Novartis Overhauls Sales Model to Prioritize Solving Regional Treatment Gaps
November 14, 2025
- Keytruda Again Tops Japan Market in July-September: IQVIA
November 14, 2025
- UK Clears Monthly IV Maintenance Dosing for Leqembi: Eisai/Biogen
November 14, 2025
- Kaken Gets Select-Asia Rights to Numab’s Multi-Specific Antibody
November 14, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…